HC Wainwright Analysts Decrease Earnings Estimates for CNTX

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for Context Therapeutics in a research note issued to investors on Tuesday, March 24th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.14) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at $0.08 EPS.

Other equities analysts have also recently issued research reports about the company. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Piper Sandler raised their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday. Finally, JonesTrading began coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Trading Up 2.0%

Shares of Context Therapeutics stock opened at $2.59 on Thursday. The stock has a 50-day moving average price of $2.48 and a 200 day moving average price of $1.63. The company has a market cap of $237.97 million, a P/E ratio of -6.82 and a beta of 1.96. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03).

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at about $43,000. Quadrature Capital Ltd acquired a new position in Context Therapeutics in the fourth quarter worth approximately $68,000. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after buying an additional 35,000 shares during the last quarter. XTX Topco Ltd raised its position in Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after acquiring an additional 91,008 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Context Therapeutics during the third quarter valued at approximately $100,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a “Strong‑Buy” rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.